Antifungal prophylaxis during neutropenia and immunodeficiency

Area of Science:

• Mycology
• Immunology
• Infectious Diseases

Background:

• Fungal infections are a significant cause of illness and death in immunocompromised individuals, including those with acquired immunodeficiency syndrome (AIDS) and hematological malignancies.
• Invasive mycoses can be acquired in healthcare settings (e.g., aspergillosis) or the community (e.g., cryptococcosis, candidiasis), posing public health challenges, especially in endemic areas with diseases like histoplasmosis, coccidioidomycosis, and penicilliosis.
• While oral azoles are available, robust clinical data on antifungal prophylactic strategies are limited, primarily focusing on specific high-risk groups.

Purpose of the Study:

• To review the current landscape of antifungal prophylaxis in immunocompromised patients.
• To identify gaps in knowledge and areas requiring further research in preventing invasive fungal infections.
• To highlight considerations for clinicians when prescribing antifungal prophylaxis.

Main Methods:

• Review of existing literature on antifungal prophylaxis in immunocompromised hosts.
• Analysis of the efficacy and limitations of current prophylactic agents, such as fluconazole.
• Identification of challenges including optimal dosing, duration, drug resistance, drug interactions, and cost.

Main Results:

• Fluconazole is effective for candidal infections in neutropenic and bone marrow transplant patients but does not always improve survival and can lead to resistant strains.
• Primary prophylaxis against aspergillosis is still under investigation.
• No universal recommendations exist for primary antifungal prophylaxis in acquired immunodeficiency syndrome (AIDS) patients or transplant recipients.
• Prolonged suppressive therapy is often necessary for patients with a history of non-candidal systemic fungal infections to prevent relapse.

Conclusions:

• Current antifungal prophylactic strategies are not fully established, with a need for better-defined protocols, especially for aspergillosis and in specific patient populations like AIDS and transplant recipients.
• Physicians must consider potential drug resistance, interactions, and costs when prescribing prophylaxis.
• Well-designed, randomized, multicenter trials are urgently required to establish evidence-based guidelines for preventing severe invasive mycoses in high-risk immunocompromised individuals.